Preliminary signs of clinical efficacy have also been observed in patients with solid tumors, including NSCLC, who received sabatolimab and anti-PD-1 antibody spartalizumab, suggesting that blockade of TIM-3 might represent a potential therapeutic strategy in lung cancer (116). This evidence concerns the gene HAVCR2 and non-small cell lung carcinoma.